Dravet Syndrome Indication Will Set GW Pharma Apart On US Epilepsy Market

GW Pharma is on track for 2017 filings for its marijuana-derived epilepsy therapy, Epidiolex (cannabidiol), following more positive data from the third Phase III study for the drug to be presented this year – however, Epidiolex's potential in Dravet syndrome will be its competitive edge to set GW apart from rivals.

Dravet Syndrome - Medical Report with Composition of Medicaments - Pills, Injections and Syringe
Epidiolex's potential in Dravet syndrome will be its competitive edge • Source: Shutterstock/Tashatuvango

GW Pharmaceuticals PLC's stock spiked at 811p on Sept. 26 – its highest value this year on the London Stock Exchange – following the publication of the third set of positive Phase III data this year for its cannabinoid Epidiolex (cannabidiol) in rare forms of pediatric epilepsy.

The most recent data from a second Phase III study in in patients with Lennox-Gastaut syndrome (LGS), a rare and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category